Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis.

Humans Spondylarthritis / diagnosis Rheumatology Antirheumatic Agents / therapeutic use Axial Spondyloarthritis Biological Products / therapeutic use Spondylitis, Ankylosing

Journal

Nature reviews. Rheumatology

ISSN: 1759-4804

Titre abrégé: Nat Rev Rheumatol

Pays: United States

ID NLM: 101500080

Informations de publication

Date de publication:
Nov 2023

Historique:

accepted: 05 09 2023

medline: 31 10 2023

pubmed: 7 10 2023

entrez: 6 10 2023

Statut: ppublish

Résumé

Axial spondyloarthritis (axSpA) comprises a spectrum of chronic inflammatory manifestations affecting the axial skeleton and represents a challenge for diagnosis and treatment. Our objective was to generate a set of evidence-based recommendations for the management of axSpA for physicians, health professionals, rheumatologists and policy decision makers in Pan American League of Associations for Rheumatology (PANLAR) countries. Grading of Recommendations, Assessment, Development and Evaluation-ADOLOPMENT methodology was used to adapt existing recommendations after performing an independent systematic search and synthesis of the literature to update the evidence. A working group consisting of rheumatologists, epidemiologists and patient representatives from countries within the Americas prioritized 13 topics relevant to the context of these countries for the management of axSpA. This Evidence-Based Guideline article reports 13 recommendations addressing therapeutic targets, the use of NSAIDs and glucocorticoids, treatment with DMARDs (including conventional synthetic, biologic and targeted synthetic DMARDs), therapeutic failure, optimization of the use of biologic DMARDs, the use of drugs for extra-musculoskeletal manifestations of axSpA, non-pharmacological interventions and the follow-up of patients with axSpA.

Identifiants

DOI: 10.1038/s41584-023-01034-z PMID: 37803079

pubmed: 37803079

doi: 10.1038/s41584-023-01034-z

pii: 10.1038/s41584-023-01034-z

doi:

Substances chimiques

Antirheumatic Agents 0

Biological Products 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Pagination

724-737

Informations de copyright

Références

Navarro-Compán, V., Sepriano, A., El-Zorkany, B. & van der Heijde, D. Axial spondyloarthritis. Ann. Rheum. Dis. 80, 1511–1521 (2021).

pubmed: 34615639 doi: 10.1136/annrheumdis-2021-221035

Rudwaleit, M. et al. The development of the Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009).

pubmed: 19297344 doi: 10.1136/ard.2009.108233

Bautista-Molano, W. et al. Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. Clin. Rheumatol. 35, 1759–1767 (2016).

pubmed: 26791876 doi: 10.1007/s10067-016-3184-2

López-Medina, C. et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open. 7, e001450 (2021).

pubmed: 33462157 pmcid: 7816910 doi: 10.1136/rmdopen-2020-001450

Stolwijk, C., van Onna, M., Boonen, A. & van Tubergen, A. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care. Res. 68, 1320–1331 (2016).

doi: 10.1002/acr.22831

Citera, G. et al. Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis. Adv. Rheumatol. 61, 2 (2021).

pubmed: 33419481 doi: 10.1186/s42358-020-00161-5

Boonen, A. et al. The burden of non-radiographic axial spondyloarthritis. Semin. Arthritis Rheum. 44, 556–562 (2015).

pubmed: 25532945 doi: 10.1016/j.semarthrit.2014.10.009

Garrido-Cumbrera, M. et al. EMAS working group. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 7, e001769 (2021).

pubmed: 34740979 pmcid: 8573671 doi: 10.1136/rmdopen-2021-001769

Moltó, A. et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann. Rheum. Dis. 75, 1016–1023 (2016).

pubmed: 26489703 doi: 10.1136/annrheumdis-2015-208174

Bautista-Molano, W. et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study. J. Rheumatol. 45, 206–212 (2018).

pubmed: 29247152 doi: 10.3899/jrheum.170520

Zhao, S. S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology 58, 1746–1754 (2019).

pubmed: 31220322 pmcid: 7967906 doi: 10.1093/rheumatology/kez119

Ramiro, S. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. 82, 19–34 (2023).

doi: 10.1136/ard-2022-223296

Reyes-Cordero, G. et al. Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. Reumatol. Clin. 17, 37–45 (2021).

pubmed: 31285162 doi: 10.1016/j.reuma.2019.03.010

Resende, G. G. et al. The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019. Adv. Rheumatol. 21, 60 (2020). 19.

Rohekar, S. et al. 2014 update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the management of spondyloarthritis. part II: specific management recommendations. J. Rheumatol. 42, 665–681 (2015).

pubmed: 25684768 doi: 10.3899/jrheum.141001

Bautista-Molano, W. et al. 2021 clinical practice guideline for the early detection, diagnosis, treatment, and monitoring of patients with axial spondyloarthritis. Colombian Association of Rheumatology. Reumatol. Clin. 18, 191–199 (2022).

pubmed: 35305953 doi: 10.1016/j.reuma.2021.09.003

Flodgren, G., O’Brien, M. A., Parmelli, E. & Grimshaw, J. M. Local opinion leaders: effects on professional practice and healthcare outcomes. Cochrane Database Syst. Rev. 24, CD000125 (2019). 6.

Ward, M. M. et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis. research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care. Res. 71, 1285–1299 (2019).

doi: 10.1002/acr.24025

Schünemann, H. J. et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J. Clin. Epidemiol. 81, 101–110 (2017).

pubmed: 27713072 doi: 10.1016/j.jclinepi.2016.09.009

Brouwers, M. C., Kerkvliet, K. & Spithoff, K., AGREE Next Steps Consortium. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. Br. Med. J. 352, i1152 (2016).

doi: 10.1136/bmj.i1152

Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603–605 (2010).

pubmed: 20652370 doi: 10.1007/s10654-010-9491-z

Guyatt, G. H. et al. Going from evidence to recommendations. Br. Med. J. 336, 1049–1051 (2008).

doi: 10.1136/bmj.39493.646875.AE

Machado, P. et al. Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann. Rheum. Dis. 70, 47–53 (2011).

pubmed: 21068095 doi: 10.1136/ard.2010.138594

Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T., Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140, 509–516 (2005).

pubmed: 16196117

Kalden, J. & Schulze-Koops, H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat. Rev. Rheumatol. 13, 707–718 (2017).

pubmed: 29158574 doi: 10.1038/nrrheum.2017.187

Molto, A. et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann. Rheum. Dis. 80, 1436–1444 (2021).

pubmed: 33958325 doi: 10.1136/annrheumdis-2020-219585

US National Library of Medicine. A study treating participants with early axial spondyloarthritis (axSpA) taking an intense treatment approach versus routine treatment (STRIKE). ClinicalTrials.gov Identifier: NCT02897115 (2019).

Sieper, J. & Poddubnyy, D. What is the optimal target for a T2T approach in axial spondyloarthritis? Ann. Rheum. Dis. 80, 1367–1369 (2021).

pubmed: 34144966 doi: 10.1136/annrheumdis-2021-220603

van Bentum, R. E. & van der Horst-Bruinsma, I. E. Axial spondyloarthritis in the era of precision medicine. Rheum. Dis. Clin. N. Am. 46, 367–378 (2020).

doi: 10.1016/j.rdc.2020.01.013

Barkhuizen, A. et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J. Rheumatol. 33, 1805–1812 (2006).

pubmed: 16960941

Benhamou, M., Gossec, L. & Dougados, M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology 49, 536–541 (2010).

pubmed: 20028728 doi: 10.1093/rheumatology/kep393

Dougados, M. et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 44, 180–185 (2001).

pubmed: 11212158 doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K

Dougados, M. et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38, 235–244 (1999).

pubmed: 10325662 doi: 10.1093/rheumatology/38.3.235

Van Der Heijde, D. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 52, 1205–1215 (2005).

pubmed: 15818702 doi: 10.1002/art.20985

Fattahi, M. J. et al. Evaluation of the efficacy and safety of β-D-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I/II clinical trial. Int. Immunopharmacol. 54, 112–117 (2018).

pubmed: 29127910 doi: 10.1016/j.intimp.2017.11.003

Fan, M. et al. Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials. Exp. Ther. Med. 19, 3031–3041 (2020).

pubmed: 32256790 pmcid: 7086213

Sieper, J. et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann. Rheum. Dis. 67, 323–329 (2008).

pubmed: 17616556 doi: 10.1136/ard.2007.075309

Mena, H. R. & Good, A. E. Management of ankylosing spondylitis with flurbiprofen or indomethacin. South. Med. J. 70, 945–947 (1977).

pubmed: 329422 doi: 10.1097/00007611-197708000-00014

Calin, A. & Britton, M. Sulindac in ankylosing spondylitis: double-blind evaluation of sulindac and indomethacin. J. Am. Med. Assoc. 242, 1885–1886 (1979).

doi: 10.1001/jama.1979.03300170031022

Sydnes, O. A. Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial. Br. J. Clin. Pract. 35, 40–44 (1981).

pubmed: 7020732 doi: 10.1111/j.1742-1241.1981.tb08215.x

Palferman, T. G. & Webley, M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur. J. Rheumatol. Inflamm. 11, 23–29 (1991).

pubmed: 1365469

Calabro, J. J. Efficacy of diclofenac in ankylosing spondylitis. Am. J. Med. 80, 58–63 (1986).

pubmed: 3518435 doi: 10.1016/0002-9343(86)90082-3

Tannenbaum, H., DeCoteau, W. E. & Esdaile, J. M. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr. Ther. Res. Clin. Exp. 36, 426–435 (1984).

Ebner, W., Poal Ballarin, J. M. & Boussina, I. Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. Arzneimittelforschung 33, 660–663 (1983).

pubmed: 6349653

Burry, H. C. & Siebers, R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. N. Z. Med. J. 92, 309–311 (1980).

pubmed: 7003449

Franssen, M. J. A. M., Gribnau, F. W. J. & Van De Putte, L. B. A. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin. Rheumatol. 5, 210–220 (1986).

pubmed: 3524970 doi: 10.1007/BF02032359

Wordsworth, B. P., Ebringer, R. W., Coggins, E. & Smith, S. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatology 19, 260–263 (1980).

doi: 10.1093/rheumatology/19.4.260

Gibson, T. & Laurent, R. Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study. Rheumatology 19, 189–192 (1980).

doi: 10.1093/rheumatology/19.3.189

Shipley, M., Berry, H. & Bloom, B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment. Rheumatology 19, 122–125 (1980).

doi: 10.1093/rheumatology/19.2.122

Sturrock, R. D. & Hart, F. D. Double blind crossover comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann. Rheum. Dis. 33, 129–131 (1974).

pubmed: 4595274 pmcid: 1006225 doi: 10.1136/ard.33.2.129

Mena, H. R. & Willkens, R. F. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur. J. Clin. Pharmacol. 11, 263–266 (1977).

pubmed: 324773 doi: 10.1007/BF00607674

Ansell, B. M. et al. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. Ann. Rheum. Dis. 37, 436–439 (1978).

pubmed: 363071 pmcid: 1000272 doi: 10.1136/ard.37.5.436

Bacon, P. A. An overview of the efficacy of etodolac in arthritic disorders. Eur. J. Rheumatol. Inflamm. 10, 22–34 (1990).

pubmed: 2146130

Wasner, C. et al. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. J. Am. Med. Assoc. 246, 2168–2172 (1981).

doi: 10.1001/jama.1981.03320190026021

Balazcs, E. et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet. Disord. 17, 426 (2016).

pubmed: 27737664 pmcid: 5062857 doi: 10.1186/s12891-016-1275-5

Huang, F. et al. Efficacy and safety of celecoxib in Chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr. Ther. Res. Clin. Exp. 76, 126–133 (2014).

pubmed: 25516774 pmcid: 4266770 doi: 10.1016/j.curtheres.2014.08.002

Walker, C., Essex, M. N., Li, C. & Park, P. W. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J. Int. Med. Res. 44, 483–495 (2016).

pubmed: 26980340 pmcid: 5536700 doi: 10.1177/0300060516628704

Van Gerwen, F., Van Der Korst, J. K. & Gribnau, F. W. J. Double blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Ann. Rheum. Dis. 37, 85–88 (1978).

pubmed: 343727 pmcid: 1000198 doi: 10.1136/ard.37.1.85

Wanders, A. et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756–1765 (2005).

pubmed: 15934081 doi: 10.1002/art.21054

Kroon, F. et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann. Rheum. Dis. 71, 1623–1629 (2012).

pubmed: 22532639 doi: 10.1136/annrheumdis-2012-201370

Poddubnyy, D. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann. Rheum. Dis. 71, 1616–1622 (2012).

pubmed: 22459541 doi: 10.1136/annrheumdis-2011-201252

Sieper, J. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann. Rheum. Dis. 75, 1438–1443 (2016).

pubmed: 26242443 doi: 10.1136/annrheumdis-2015-207897

Maugars, Y., Mathis, C., Berthelot, J. M., Charlier, C. & Prost, A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br. J. Rheumatol. 35, 767–770 (1996).

pubmed: 8761190 doi: 10.1093/rheumatology/35.8.767

Luukkainen, R. et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin. Exp. Rheumatol. 17, 88–90 (1999).

pubmed: 10084038

Günaydin, I., Pereira, P. L., Fritz, J., König, C. & Kötter, I. Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial? Rheumatol. Int. 26, 396–400 (2006).

pubmed: 16010559 doi: 10.1007/s00296-005-0008-0

Migliore, A. et al. A new technical contribution for ultrasound-guided injections of sacro-iliac joints. Eur. Rev. Med. Pharmacol. Sci. 14, 465–469 (2010).

pubmed: 20556926

Nam, B. et al. Efficacy and safety of intra-articular sacroiliac glucocorticoid injections in ankylosing spondylitis. J. Clin. Rheumatol. 28, e26–e32 (2022).

pubmed: 33298816 doi: 10.1097/RHU.0000000000001584

Dhir, V., Mishra, D. & Samanta, J. Glucocorticoids in spondyloarthritis — systematic review and real-world analysis. Rheumatology 60, 4463–4475 (2021).

pubmed: 33748829 doi: 10.1093/rheumatology/keab275

Nissilä, M. et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 31, 1111–1116 (1988).

pubmed: 2901839 doi: 10.1002/art.1780310905

Taylor, H. G., Beswick, E. J. & Dawes, P. T. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin. Rheumatol. 10, 43–48 (1991).

pubmed: 1676621 doi: 10.1007/BF02208032

Dougados, M., Boumier, P. & Amor, B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br. Med. J. 293, 911–914 (1986).

doi: 10.1136/bmj.293.6552.911

Davis, M. J., Dawes, P. T., Beswick, E., Lewin, I. V. & Stanworth, D. R. Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin a-alpha-1-antitrypsin. Rheumatology 28, 410–413 (1989).

doi: 10.1093/rheumatology/28.5.410

Corkill, M. M., Jobanputra, P., Gibson, T. & Macfarlane, D. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Rheumatology 29, 41–45 (1990).

doi: 10.1093/rheumatology/29.1.41

Kirwan, J., Edwards, A., Huitfeldt, B., Thompson, P. & Currey, H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Rheumatology 32, 729–733 (1993).

doi: 10.1093/rheumatology/32.8.729

Clegg, D. O. et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum. 39, 1911–1912 (1996).

doi: 10.1002/art.1780391209

Feltelius, N. & Hallgren, R. Sulphasalazine in ankylosing spondylitis. Ann. Rheum. 45, 396–399 (1986).

doi: 10.1136/ard.45.5.396

Khanna Sharma, S., Kadiyala, V., Naidu, G. & Dhir, V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int. J. Rheum. Dis. 21, 308 (2018).

pubmed: 28737251 doi: 10.1111/1756-185X.13124

Venkatesh, S., Vishad, V., Viswanath, V., Deepak, T. & Mehtab, A. A prospective double blind placebo controlled trial of combination disease modifying antirheumatic drugs vs monotherapy (sulfasalazine) in patients with inflammatory low backache in ankylosing spondylitis and undifferentiated spondyloarthropathy. J. Arthritis S1 1041722167-7921S1-001 (2015).

Roychowdhury, B. et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology 41, 1330–1332 (2002).

pubmed: 12422010 doi: 10.1093/rheumatology/41.11.1330

Altan, L. et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 30, 255–259 (2001).

pubmed: 11727838 doi: 10.1080/030097401753180318

Gonzalez-Lopez, L., Garcia-Gonzalez, A., Vazquez-Del-Mercado, M., Muñoz-Valle, J. F. & Gamez-Nava, J. I. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J. Rheumatol. 31, 1568–1574 (2004).

pubmed: 15290737

Haibel, H. et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann. Rheum. Dis. 66, 419–421 (2007).

pubmed: 16901959 doi: 10.1136/ard.2006.054098

Van Denderen, J. C. et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. 64, 1761–1764 (2005).

pubmed: 15901634 pmcid: 1755327 doi: 10.1136/ard.2005.036491

Dougados, M. & Wei, J. C. et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann. Rheum. Dis. 79, 176–185 (2020).

pubmed: 31685553 doi: 10.1136/annrheumdis-2019-216118

Kiltz, U. & Wei, J. C. et al. Ixekizumab improves functioning and health in the treatment of radiographic axial spondyloarthritis: week 52 results from 2 pivotal studies. J. Rheumatol. 48, 188–197 (2021).

pubmed: 32669450 doi: 10.3899/jrheum.200093

Wu, Y. et al. Model-based meta-analysis in ankylosing spondylitis: a quantitative comparison of biologics and small targeted molecules. Clin. Pharmacol. Ther. 105, 1244–1255 (2019).

pubmed: 30450610 doi: 10.1002/cpt.1305

Van Der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340–1347 (2017).

pubmed: 28130206 doi: 10.1136/annrheumdis-2016-210322

Deodhar, A. et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 80, 1004–1013 (2021).

pubmed: 33906853 doi: 10.1136/annrheumdis-2020-219601

van der Heijde, D. S. I. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 394, 2108–2117 (2019).

pubmed: 31732180 doi: 10.1016/S0140-6736(19)32534-6

van der Heijde, D. B. X. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2378–2387 (2018).

pubmed: 30360970 doi: 10.1016/S0140-6736(18)32463-2

Ytterberg, S. R. et al. ORAL surveillance investigators. cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).

pubmed: 35081280 doi: 10.1056/NEJMoa2109927

Mulleman, D. et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res. Ther. 13, R82 (2011).

pubmed: 21639907 pmcid: 3218893 doi: 10.1186/ar3350

Li, E. K. et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 47, 1358–1363 (2008).

pubmed: 18573802 doi: 10.1093/rheumatology/ken207

Nissen, M. J. et al. The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti–tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol. 68, 2141–2150 (2016).

pubmed: 27015429 doi: 10.1002/art.39691

Pérez-Guijo, V. C. et al. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74, 254–258 (2007).

pubmed: 17387031 doi: 10.1016/j.jbspin.2006.08.005

Nissen, M. et al. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology 61, 4741–4751 (2022).

pubmed: 35323903 doi: 10.1093/rheumatology/keac174

Park, W. et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res. Ther. 18, 25 (2016).

pubmed: 26795209 pmcid: 4721187 doi: 10.1186/s13075-016-0930-4

Xu, H. & Zhijun, L. et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 1, e35 (2019).

doi: 10.1016/S2665-9913(19)30013-X

Su, J. & Li, M. et al. Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase III clinical trial. BioDrugs 34, 381–393 (2020).

pubmed: 32078145 pmcid: 7211209 doi: 10.1007/s40259-020-00408-z

Lindström, U. et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD Open 5, e001079 (2019).

pubmed: 31749988 pmcid: 6827791 doi: 10.1136/rmdopen-2019-001079

Kowalski, S. C. et al. PANLAR consensus statement on biosimilars. Clin. Rheumatol. 38, 1485–1496 (2019).

pubmed: 30915652 doi: 10.1007/s10067-019-04496-3

Deodhar, A. et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400, 369–379 (2022).

pubmed: 35908570 doi: 10.1016/S0140-6736(22)01212-0

McInnes, I. B. et al. FUTURE 2 Study Group. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res. Ther. 20, 113 (2018).

pubmed: 29880010 pmcid: 5992664 doi: 10.1186/s13075-018-1610-3

Kavanaugh, A. et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J. Rheumatol. 43, 1713–1717 (2016).

pubmed: 27307536 doi: 10.3899/jrheum.160275

Guignard, S. et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann. Rheum. Dis. 65, 1631–1634 (2006).

pubmed: 16901960 pmcid: 1798480 doi: 10.1136/ard.2006.052092

Braun, J., Baraliakos, X., Listing, J. & Sieper, J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52, 2447–2451 (2005).

pubmed: 16052578 doi: 10.1002/art.21197

Cobo-Ibáñez, T., del Carmen Ordóñez, M., Muñoz-Fernández, S., Madero-Prado, R. & Martín-Mola, E. Do TNF-blockers reduce or induce uveitis? Rheumatology 47, 731–732 (2008).

pubmed: 18346974 doi: 10.1093/rheumatology/ken091

Fouache, D. et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 48, 761–764 (2009).

pubmed: 19395543 doi: 10.1093/rheumatology/kep083

Rudwaleit, M. et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68, 696–701 (2009).

pubmed: 18662932 doi: 10.1136/ard.2008.092585

Lee, S., Park, Y. J. & Lee, J. Y. The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis. J. Korean Med. Sci. 34, e278 (2019).

pubmed: 31674159 pmcid: 6823519 doi: 10.3346/jkms.2019.34.e278

Lindström, U. et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann. Rheum. Dis. 80, 1445–1452 (2021).

pubmed: 34130984 doi: 10.1136/annrheumdis-2021-220420

Lamb, C. A. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68, s1–s106 (2019).

pubmed: 31562236 doi: 10.1136/gutjnl-2019-318484

Kornbluth, A. & Sachar, D. B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology practice parameters committee. Am. J. Gastroenterol. 105, 501–523 (2010).

pubmed: 20068560 doi: 10.1038/ajg.2009.727

Lichtenstein, G. R. et al. ACG clinical guideline: management of Crohn’s disease in adults. Am. J. Gastroenterol. 113, 481–517 (2018).

pubmed: 29610508 doi: 10.1038/ajg.2018.27

Sandborn et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736 (2017).

pubmed: 28467869 doi: 10.1056/NEJMoa1606910

Hueber et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).

pubmed: 22595313 doi: 10.1136/gutjnl-2011-301668

Chen, X., Zhang, T., Wang, W. & Xue, J. Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin. Rheumatol. 37, 1625–1632 (2018).

pubmed: 29667099 doi: 10.1007/s10067-018-4084-4

Li, J. et al. Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. Int. J. Immunopathol. Pharmacol. 29, 510–515 (2016).

pubmed: 27381286 pmcid: 5806770 doi: 10.1177/0394632016656013

Cantini, F., Niccoli, L., Cassarà, E., Kaloudi, O. & Nannini, C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biol. Targets Ther. 7, 1–6 (2013).

Yates, M. et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J. Rheumatol. 42, 1175–1185 (2015).

doi: 10.3899/jrheum.141335

Lian, F. et al. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin. Exp. Rheumatol. 36, 884–890 (2018).

pubmed: 29652659

Lawson, D. O. et al. Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta‐analysis of randomized controlled trials. Arthritis Care. Res. 73, 861–872 (2021).

doi: 10.1002/acr.24184

Arends, S. et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin. Exp. Rheumatol. 33, 174–180 (2015).

pubmed: 25797228

Lee, S.-H., Lee, Y.-A., Hong, S.-J. & Yang, H.-I. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin. Rheumatol. 27, 179–181 (2008).

pubmed: 17874173 doi: 10.1007/s10067-007-0674-2

Almirall, M. et al. Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy. Rheumatol. Int. 36, 575–578 (2016).

pubmed: 26815206 doi: 10.1007/s00296-016-3428-0

De Stefano, R., Frati, E., De Quattro, D., Menza, L. & Manganelli, S. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin. Rheumatol. 33, 707–711 (2014).

pubmed: 24062201 doi: 10.1007/s10067-013-2372-6

Plasencia, C. et al. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J. Rheumatol. 42, 1638–1646 (2015).

pubmed: 26178279 doi: 10.3899/jrheum.141128

Závada, J. et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann. Rheum. Dis. 75, 96–102 (2016).

pubmed: 25165033 doi: 10.1136/annrheumdis-2014-205202

Navarro-Compán, V. et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin. Rheumatol. 30, 993–996 (2011).

pubmed: 21373780 doi: 10.1007/s10067-011-1722-5

Lee, J. et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin. Rheumatol. 29, 1149–1154 (2010).

pubmed: 20683738 doi: 10.1007/s10067-010-1542-z

Paccou, J., Baclé-Boutry, M. A., Solau-Gervais, E., Bele-Philippe, P. & Flipo, R. M. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J. Rheumatol. 39, 1418–1423 (2012).

pubmed: 22707611 doi: 10.3899/jrheum.111337

Fong, W. et al. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatology 55, 1837–1842 (2016).

pubmed: 27354684 doi: 10.1093/rheumatology/kew269

Park, J. W. et al. Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. PLoS One 11, e0168958 (2016).

pubmed: 28033420 pmcid: 5199008 doi: 10.1371/journal.pone.0168958

Mörck, B., Pullerits, R., Geijer, M., Bremell, T. & Forsblad-d’Elia, H. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm. 2013, 289845 (2013).

pubmed: 24089587 pmcid: 3780705 doi: 10.1155/2013/289845

Chen, M. H. et al. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin. Rheumatol. 37, 429–438 (2018).

pubmed: 29307092 doi: 10.1007/s10067-017-3965-2

Landewé, R. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392, 134–144 (2018).

pubmed: 29961640 doi: 10.1016/S0140-6736(18)31362-X

Moreno, M. et al. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Res. Ther. 21, 88 (2019).

pubmed: 30953541 pmcid: 6451276 doi: 10.1186/s13075-019-1873-3

Baraliakos, X. et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. 7, R439–R444 (2005).

pubmed: 15899030 pmcid: 1174938 doi: 10.1186/ar1693

Deng, X., Zhang, J., Zhang, J. & Huang, F. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol. Int. 33, 1409–1413 (2013).

pubmed: 23143621 doi: 10.1007/s00296-012-2571-5

Breban, M. et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41, 1280–1285 (2002).

pubmed: 12422001 doi: 10.1093/rheumatology/41.11.1280

Heldmann, F. et al. The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 29, 672–680 (2011).

pubmed: 21906431

Zhao, M. et al. Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years’ following-up study. Clin. Rheumatol. 37, 87–92 (2018).

pubmed: 28785857 doi: 10.1007/s10067-017-3763-x

Sebastian, A. et al. Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. Reumatologia 55, 87–92 (2017).

doi: 10.5114/reum.2017.69775

Brandt, J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48, 1667–1675 (2003).

pubmed: 12794835 doi: 10.1002/art.11017

Kjeken, I. et al. A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J. Rehabil. Med. 45, 260–267 (2013).

pubmed: 23138412 doi: 10.2340/16501977-1078

Bulstrode, S. J., Barefoot, J., Harrison, R. A. & Clarke, A. K. The role of passive stretching in the treatment of ankylosing spondylitis. Rheumatology 26, 40–42 (1987).

doi: 10.1093/rheumatology/26.1.40

Cozzi, F. et al. Mud-bath treatment in spondylitis associated with inflammatory bowel disease — a pilot randomised clinical trial. Joint Bone Spine 74, 436–439 (2007).

pubmed: 17590368 doi: 10.1016/j.jbspin.2006.12.003

Viitanen, J. V. & Heikkilä, S. Functional changes in patients with spondylarthropathy. A controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol. Int. 20, 211–214 (2001).

pubmed: 11518042 doi: 10.1007/s002960100101

Altan, L., Korkmaz, N., Dizdar, M. & Yurtkuran, M. Effect of Pilates training on people with ankylosing spondylitis. Rheumatol. Int. 32, 2093–2099 (2012).

pubmed: 21499876 doi: 10.1007/s00296-011-1932-9

Durmus, D., Alayli, G., Cil, E. & Canturk, F. Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol. Int. 29, 673–677 (2009).

pubmed: 18985351 doi: 10.1007/s00296-008-0756-8

Durmuş, D. et al. Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76, 150–155 (2009).

pubmed: 19084457 doi: 10.1016/j.jbspin.2008.06.013

Rodríguez-Lozano, C. et al. Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomised study. Clin. Exp. Rheumatol. 31, 739–748 (2013).

pubmed: 23899791

Kraag, G., Stokes, B., Groh, J., Helewa, A. & Goldsmith, C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - a randomized controlled trial. J. Rheumatol. 17, 261–263 (1990).

Gemignani, G., Olivieri, I., Ruju, G. & Pasero, G. Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study. Arthritis Rheum. 34, 788–789 (1991).

pubmed: 1828944 doi: 10.1002/art.1780340624

Ince, G., Sarpel, T., Durgun, B. & Erdogan, S. Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys. Ther. 86, 924–935 (2006).

pubmed: 16813473 doi: 10.1093/ptj/86.7.924

Niedermann, K. et al. Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis. Arthritis Care Res. 65, 1844–1852 (2013).

doi: 10.1002/acr.22062

Widberg, K., Hossein, K. & Hafström, I. Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis — a randomized study. Clin. Rehabil. 23, 599–608 (2009).

pubmed: 19403551 doi: 10.1177/0269215508101748

Masiero, S. et al. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy. A randomized controlled trial. J. Rheumatol. 38, 1335–1342 (2011).

pubmed: 21459942 doi: 10.3899/jrheum.100987

Masiero, S. et al. Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clin. Rehabil. 28, 562–572 (2014).

pubmed: 24285801 doi: 10.1177/0269215513512214

Ernst, E. Adverse effects of spinal manipulation: a systematic review. J. R. Soc. Med. 100, 330–338 (2007).

pubmed: 17606755 pmcid: 1905885 doi: 10.1177/014107680710000716

Hebert, J. J., Stomski, N. J., French, S. D. & Rubinstein, S. M. Serious adverse events and spinal manipulative therapy of the low back region: a systematic review of cases. J. Manipulative Physiol. Ther. 38, 677–691 (2015).

pubmed: 23787298 doi: 10.1016/j.jmpt.2013.05.009

Carnes, D., Mars, T. S., Mullinger, B., Froud, R. & Underwood, M. Adverse events and manual therapy: a systematic review. Man. Ther. 15, 355–363 (2010).

pubmed: 20097115 doi: 10.1016/j.math.2009.12.006

Rinsky, L. A., Reynolds, G. G., Jameson, R. M. & Hamilton, R. D. A cervical spinal cord injury following chiropractic manipulation. Paraplegia 13, 223–227 (1976).

pubmed: 1264476

Liao, C. C. & Chen, L. R. Anterior and posterior fixation of a cervical fracture induced by chiropractic spinal manipulation in ankylosing spondylitis: a case report. J. Trauma 63, E90–E94 (2007).

pubmed: 18089996

Navarro-Compan, V. et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin. Arthritis Rheum. 51, 1342–1349 (2021).

pubmed: 34489113 doi: 10.1016/j.semarthrit.2021.07.021

Schneeberger E. E. et al. Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) versus ASDAS: a post hoc analysis of a randomized controlled trial. J. Rheumatol. 49, 1100–1108 (2022).

pubmed: 35840157 doi: 10.3899/jrheum.211075

Vosse, D. et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann. Rheum. Dis. 68, 1839–1842 (2009).

pubmed: 19066179 doi: 10.1136/ard.2008.100503

Weiss, R. J., Wick, M. C., Ackermann, P. W. & Montgomery, S. M. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases — a case-control study with 53,108 patients with fracture. J. Rheumatol. 37, 2247–2250 (2010).

pubmed: 20889599 doi: 10.3899/jrheum.100363

Brance, M. L. et al. Argentine guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in postmenopausal women and men aged 50 years and older. J. Clin. Rheumatol. 29, e59–e70 (2023).

pubmed: 37005371 doi: 10.1097/RHU.0000000000001951

Baraliakos, X. et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study [abstract]. Arthritis Rheumatol. 74, https://acrabstracts.org/abstract/effect-of-secukinumab-versus-adalimumab-biosimilar-on-radiographic-progression-in-patients-with-radiographic-axial-spondyloarthritis-a-randomized-phase-iiib-study/ (accessed 10 June 2023).